HSKA - HSKA STOCK NEWS

Spruce Point Capital Management released a report predicting a 50% - 60% downside risk for Heska Corporation (HSKA), potentially dropping shares to $90.00. The report questions the company's claims regarding organic growth and market share, indicating recent acquisitions have low-quality assets. Concerns were also raised about Heska's new product, Element AIM, which appears to have limited veterinarian interest and is behind a competitor's launch. Governance issues, inconsistent financial disclosures, and an inflated market valuation were highlighted as additional red flags.

Heska Corporation (NASDAQ: HSKA) will release its third quarter 2021 financial results before the market opens on November 4, 2021. An earnings call is scheduled for 9 a.m. MT (11 a.m. ET) to discuss the outcomes. Investors can join the call by dialing specified numbers, with a conference ID of 2365183. A telephonic replay will be available starting at 2 p.m. ET on November 4 until November 18, 2021. Heska specializes in veterinary diagnostic and specialty products globally, offering various healthcare products and services.

Heska Corporation (NASDAQ: HSKA) has acquired majority ownership of Biotech Laboratories U.S.A. LLC to enhance its veterinary diagnostics portfolio. This acquisition, effective September 1, 2021, allows Heska to enter the rapidly growing market for point-of-care diagnostics, estimated at $500 million globally. Biotech's advanced rapid assay tests contribute to Heska's commitment to innovating veterinary care. The transaction strengthens Heska's product line and intellectual property, positioning it to compete effectively in this segment.

Heska Corporation has appointed Anthony Providenti as Executive Vice President of Corporate Development to boost its corporate growth strategies. With over 25 years of experience, Providenti previously served at Covetrus Inc. and brings a wealth of industry knowledge. CEO Kevin Wilson lauded Providenti's track record in driving growth and creating value through strategic transactions. Heska focuses on advanced veterinary diagnostic solutions and aims to leverage Providenti's expertise to enhance operational efficiency and market positioning.

Heska Corporation (NASDAQ: HSKA) reported strong financial results for Q2 2021, achieving a record revenue of $64.9 million, up 42.0% year-over-year. North America and International revenues reached $40.5 million and $24.4 million, respectively. The consolidated gross margin improved to 42.0%, an increase of 290 bps. However, the company reported a net loss of $0.6 million, with an EPS of $(0.06). Heska raised its 2021 revenue outlook to $250-$260 million, reflecting robust growth in Point of Care Lab products.

Heska Corporation (NASDAQ: HSKA) will announce its second quarter 2021 financial performance on August 3, 2021, prior to market opening. An earnings call is scheduled for 9 a.m. MT / 11 a.m. ET to discuss the results. Interested parties can access the call via a dedicated phone line or a live webcast on the investor relations website. A telephonic replay will be available from 2 p.m. ET on August 3 until 11:59 p.m. ET on August 17, 2021. The company specializes in veterinary diagnostics and healthcare products across North America and internationally.

Heska Corporation (NASDAQ: HSKA) will have its President and CEO, Kevin Wilson, presenting at two virtual conferences in June 2021. The first event is the Stifel 2021 Virtual Jaws & Paws Conference on June 3 at 1:00 p.m. ET, with a webcast available for replay. The second is the Jefferies Virtual Healthcare Conference on June 4 at 9:30 a.m. ET, also followed by a webcast replay. Heska specializes in advanced veterinary diagnostic products across North America and internationally, including point-of-care lab tests and digital imaging solutions.

Heska Corporation (NASDAQ: HSKA) reported impressive first-quarter 2021 results with consolidated revenue of $60.5 million, marking a 97.4% increase year-over-year. North America revenue rose by 34.8% to $37.3 million, driven by significant growth in POC Lab Consumables sales, which were up 23.9%. The company's net income soared 135.4% year-over-year to $1.9 million, with diluted EPS reaching $0.19. Despite a 180 basis point decline in consolidated gross margin to 42.1%, Heska remains optimistic about several upcoming product launches and a strong liquidity position of $238.5 million.

Heska Corporation (NASDAQ: HSKA) has announced its 2021 Annual Meeting of Stockholders, set for May 5, 2021, at 9 a.m. MT/11 a.m. ET. The meeting will be held virtually due to COVID-19 precautions. Stockholders of record as of March 8, 2021, are eligible to participate and vote. An online proxy voting process is available as detailed in the company's proxy materials. A webcast will be accessible for all interested parties, with an archive available for 90 days post-event.